XML 63 R11.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Organization and Principal Activities | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Organization and Principal Activities | Organization and Principal Activities Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States. As of December 31, 2023, the Company’s significant operating subsidiaries were as follows:
Name of Company |  | Place of Incorporation |  | Date of Incorporation |  | Percentage of Ownership |  | Principal Activities
Zai Lab (Hong Kong) Limited |  | Hong Kong |  | April 29, 2013 |  | 100% |  | Operating company for business development and R&D activities and commercialization of innovative medicines and device
Zai Lab (Shanghai) Co., Ltd. |  | Mainland China |  | January 6, 2014 |  | 100% |  | Development and commercialization of innovative medicines and devices
Zai Lab (AUST) Pty. Ltd. |  | Australia |  | December 10, 2014 |  | 100% |  | Clinical trial activities
Zai Lab (Suzhou) Co., Ltd. |  | Mainland China |  | November 30, 2015 |  | 100% |  | Development and commercialization of innovative medicines
Zai Biopharmaceutical (Suzhou) Co., Ltd. |  | Mainland China |  | June 15, 2017 |  | 100% |  | Development and commercialization of innovative medicines
Zai Lab (US) LLC |  | United States |  | April 21, 2017 |  | 100% |  | Operating company for business development, R&D activities and certain business activities, including legal, compliance and communication functions of the Company
Zai Lab International Trading (Shanghai) Co., Ltd. |  | Mainland China |  | November 6, 2019 |  | 100% |  | Commercialization of innovative medicines and devices
Zai Auto Immune (Hong Kong) Limited |  | Hong Kong |  | November 4, 2020 |  | 100% |  | Operating company for business development and R&D activities
Zai Lab (Taiwan) Limited |  | Taiwan |  | December 10, 2020 |  | 100% |  | Commercialization of innovative medicines and devices
Zai Lab Trading (Suzhou) Co., Ltd. |  | Mainland China |  | October 27, 2020 |  | 100% |  | Commercialization of innovative medicines and devices

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration